Progress and regression within primary Sjögren's syndrome

Scandinavian Journal of Rheumatology

Volumn 35, Issue 1, 2006, Pages 1-6

  Manthorpe, R ^a   Bredberg, A ^a,b   Henriksson, G ^a,b   Larsson, A ^a,c  

^a Sjogren's Syndrome Research Centre   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c MALMÖ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BROMHEXINE; CEVIMELINE; DIHOMO GAMMA LINOLENIC ACID; ETANERCEPT; GAMMA LINOLENIC ACID; GLUCOCORTICOID; IMMUNOGLOBULIN G4; INFLIXIMAB; PILOCARPINE; RITUXIMAB;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CUSHINGOID SYNDROME; DIAGNOSTIC PROCEDURE; DISEASE COURSE; HUMAN; NONHODGKIN LYMPHOMA; PATHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATIC DISEASE; SJOEGREN SYNDROME; SYSTEMIC DISEASE;

ANTIBODIES, MONOCLONAL; BROMHEXINE; EXPECTORANTS; HUMANS; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; SJOGREN'S SYNDROME;

EID: 32644468914     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740500537945     Document Type: Review

References (46)

1. Manthorpe R, Manthorpe T. [Primary Sjögren's Syndrom - Epidemiology and Prognosis] German. Akt Rheumatol 2005;30:27-31.
2. Fox RI. Sjögren's syndrome. Lancet 2005;366:321-31.
3. Venables PJ. Sjögren's syndrome. Best Pract Res Clin Rheumatol 2004;18:313-29.
4. Proceedings of: 1st International Seminar on Sjögren's Syndrome 1986. Copenhagen, May, 1986, Scand J Rheumatol Suppl 1986;61:1-291.
5. Carlsson M. Henrik Sjögren - a medical historical presentation. Hygiea 1999;108:1-3.
6. Kok MR. Use of localized gene transfer to develop novel treatment strategies for the salivary component of Sjögren's syndrome. Thesis. University of Amsterdam, 2005:1-157.
7. The 100-year anniversary of Henrik Sjögren, September 1999, Jönköping, Sweden. Hygiea 1999;108:1-114, .
8. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-7.
9. Vitali C, Moutsopoulos HM, Bombardieri S, the European Community Study Group on Diagnostic Criteria for Sjögren's Syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis 1994;53:637-47.
10. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, the European Community Study Group on Diagnostic Criteria for Sjögren's Syndrome. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1996;55:116-21.
11. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. J Rheumatol 2002;29:938-44.
12. Sjögren H. [Knowlegde of Keratoconjunctivitis sicca] German. Acta Ophthalmol 1933;11:1-151.
13. Asmussen K, Andersen V, Bendixen G, Schiødt M, Oxholm P. A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study. Intern Med 1996;239:475-82.
14. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carssons SE, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002;61:554-8.
15. Daniels TE. Labial salivary gland biopsy in Sjögren's syndrome: assessment on a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984;27:147-56.
16. Manthorpe R, Benoni C, Jacobsson L, Kirtava Z, Larsson A, Liedholm R, et al. Lower frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren's syndrome? Ann Rheum Dis 2000;59:54-60.
17. Wiik AS. Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 2005;34:260-8.
18. Segerberg-Konttinen M. Focal sialadenitis in lacrimal and salivary glands. A post-mortem study. Scand J Rheumatol 1985;17:379-85.
19. Radfar L, Kleiner DE, Fox PC, Pillemer SR. Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Care Res 2002;47:520-4.
20. Kassan SS, Thomas T, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
21. Voulgarelis M, Dafni U, Isenberg D, Moutsopoulos HM, Jonsson R, Haga H-J, et al. Malignant lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1999;42:1765-72.
22. Ioannidis JP, Vassliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification in primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7.
23. Sutcliffe NN, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 1998;28:80-7.
24. Theander E. Living and dying with primary Sjögren's syndrome. Studies on aetiology, treatment, lymphoma, survival and predictors. Thesis. Lund University, Malmö, 2005.
25. Kirtava Z, Blomberg J, Bredberg A, Henriksson G, Jacobsson L, Manthorpe R. CD4+ T-lymphocytopenia without HIV infection: increased prevalence among patients with primary Sjögren's syndrome. Clin Exp Rheumatol 1995;13:609-16.
26. Mandl T, Bredberg A, Jacobsson L, Manthorpe R, Henriksson G. CD+ T-lymphocytopenia - a frequent finding in anti-SSA positive patients with primary Sjögren's syndrome. J Rheumatol 2004;31:726-8.
27. Manthorpe R, Oxholm P, Prause JU, Schiødt M. The Copenhagen criteria for Sjögren's syndrome. Scand J Rheumatol 1986;Suppl 61:19-21.
28. Isager H, Frost-Larsen K, Manthorpe R. Remission in a patient with Sjögren's syndrome induced by bromhexine. Ugeskr Læger 1977;139:3003-4.
29. Frost-Larsen K, Isager H, Manthorpe R. Sjögren's syndrome treated with bromhexine: a randomised clinical study. Br Med J 1978;i:1579-81.
30. Manthorpe R, Frost-Larsen K, Isager H, Prause JU. Lack of lacrimal gland improvement by NA-872 in Sjögren's syndrome. Acta Ophthalmol 1981;59:428-9.
31. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren's syndrome. Arch Intern Med 1999;159:174-81.
32. Oxholm P, Prause JU, Schiødt M. Rational drug therapy recommendations for the treatment of patients with Sjögren's syndrome. Drugs 1998;56:345-53.
33. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
34. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled trial of remicade in primary Sjögren's syndrome. Arthritis Rheum 2004;50:1270-6.
35. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjögren's syndrome. A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5.
36. Eisenberg R. Update on rituximab. Ann Rheum Dis 2005;64 Suppl 4:iv55-7.
37. Larsson Å, Bredberg A, Henriksson G, Manthorpe R, Sallmyr A. Immunohistochemistry of the B-cell component in lower lip salivary glands of Sjögren's syndrome and healthy subjects. Scand J Immunol 2005;61:98-107.
38. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus in primary Sjögren's syndrome. Arthritis Rheum 2004;50:2897-902.
39. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5.
40. Bredberg A, Henriksson G, Larsson Å, Manthorpe R, Sallmyr A. Sjögren's syndrome and the danger model. Rheumatology 2005;44:965-70.
41. Bredberg A, Manthorpe R, Henriksson G. Recent findings shed light on the aethiopathogenesis of Sjögren's syndrome. Akt Rheumatol 2005;30:1-4.
42. Matzinger P. The danger model. Vox Sang 2004;87 Suppl 2:18.
43. Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5.
44. Tsubota K, Fujita H, Tsuzaka K, Takeuchi T. Mikulicz's disease and Sjögren's syndrome. Invest Ophthalmol Vis Sci 2000;41:1666-73.
45. Yamamoto M, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, Takahashi H, et al. Elevated IgG4 concentrations in serum of patients with Mikulicz's disease. Scand J Rheumatol 2004;33:432-3.
46. Yamamoto M, Harada S, Ohara M, Suzuki C, Naishiro Y, Yamamoto H, et al. Clinical and pathological differences between Mikulicz's disease and Sjögren's syndrome. Rheumatology (Oxford) 2005;44:227-34.